{
    "url_original": "https://www.wsj.com/articles/moderna-revenue-triples-on-soaring-covid-19-vaccine-sales-11651666883?mod=business_lead_pos11",
    "url": "moderna-revenue-triples-on-soaring-covid-19-vaccine-sales-11651666883",
    "title": "Moderna Revenue Triples on Soaring Covid-19 Vaccine Sales",
    "sub_head": "Biotechnology company is latest drugmaker to post surging sales tied to demand for Covid-19 vaccines, treatments",
    "category_1": "Business",
    "category_2": "Earnings",
    "image_1_url": "https://images.wsj.net/im-535745?width=860&height=573",
    "image_1": "im-535745.jpg",
    "time": "2022-05-04 08:21:00",
    "body": "Moderna Inc.’s  first-quarter sales tripled from a year ago on the back of its Covid-19 vaccine.<br />The biotechnology company’s revenue topped $6 billion in the period ended March 31, beating analyst expectations, driven almost entirely by sales of its mRNA-based vaccine.  It is the latest drugmaker to show surging sales due to demand for Covid-19 vaccines and treatments, following recent reports from  Eli Lilly  & Co.,  Merck  & Co. and  Pfizer Inc."
}